Key Point: The incidence of statin-associated rhabdomyolysis across large clinical trials is <0.1%.

Large randomized, controlled trials indicate a low incidence of rhabdomyolysis
with statin therapy.  A recent review of major trials identified only 7 cases of rhabdomyolysis among more than 42,000 patients randomly assigned to
receive statin therapy1

The reported incidence of fatal rhabdomyolysis with statin therapy is extremely rare—0.15 deaths per 1 million prescriptions2

References

1. Thompson PD et al. Statin-associated myopathy. JAMA. 2003;289:1681-1690.

2. Staffa JA et al. Cerivastatin and reports of fatal rhabdomyolysis. N Engl J Med. 2002;346:539-540.